Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Precision Transfusion Medicine in the Omics Era.

Blood·2026

Same author

Genetic architecture of the murine serum metabolome reveals carboxyl esterases as master regulators of circulating fatty acid metabolism.

bioRxiv : the preprint server for biology·2026

Same author

Resolution of inflammation increases erythropoiesis.

Blood. Red cells & iron·2026

Same author

FATP2-mediated lipid metabolism enhances chimeric antigen receptor T-cell therapy resistance in B-cell acute lymphoblastic leukemia.

Leukemia·2026

Same author

Exposure to perfluorooctanoic acid accelerates <i>Drosophila melanogaster</i> juvenile development and disrupts mitochondrial metabolism.

bioRxiv : the preprint server for biology·2026

Same author

Blood Cells Far from Equilibrium: Redox Adaptation in Health and Disease.

Antioxidants (Basel, Switzerland)·2026

Search research articles

Related Experiment Video

Updated: Jun 17, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Repurposing NAMPT Inhibitors for Germinal Center B Cell-Like Diffuse Large B-Cell Lymphoma.

Claudio Scuoppo^1,2, Bowen Cai¹, Kenneth Ofori^1,2

¹Institute for Cancer Genetics, Vagelos College of Physicians and Surgeons, Columbia University, New York, New York.

Blood Cancer Discovery

|August 6, 2024

Summary

This summary is machine-generated.

Nicotinamide phosphoribosyl transferase inhibitors (NAMPTi) show activity against a subset of germinal center B-cell-like diffuse large B-cell lymphoma (GCB-DLBCL). The NAMPT:PARP1 ratio predicts sensitivity, especially in BCL2-translocated GCB-DLBCL.

More Related Videos

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Related Experiment Videos

Last Updated: Jun 17, 2025

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Flow Cytometry-based Assay for the Monitoring of NK Cell Functions

Published on: October 30, 2016

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Quantifying Antibody-Dependent Cellular Cytotoxicity in a Tumor Spheroid Model: Application for Drug Discovery

Published on: April 26, 2024

Area of Science:

Oncology
Molecular Biology
Pharmacology

Background:

Diffuse large B-cell lymphoma (DLBCL) comprises activated B cell-like (ABC) and germinal center B cell-like (GCB) subtypes with distinct characteristics.
Targeted therapies exist for ABC-DLBCL, but effective treatments for high-risk GCB-DLBCL remain limited.

Purpose of the Study:

To screen existing drugs for subtype-specific activity in DLBCL.
To identify novel therapeutic strategies for GCB-DLBCL, particularly those with BCL2 translocations.

Main Methods:

Screening of 211 approved or clinically developing drugs for activity against DLBCL subtypes.
Biochemical and genetic rescue approaches to validate nicotinamide phosphoribosyl transferase inhibitors (NAMPTi).
Analysis of NAMPT:PARP1 RNA ratio as a predictive biomarker for NAMPTi sensitivity.

Main Results:

NAMPT inhibitors demonstrated activity in a subset of GCB-DLBCL in vitro and in vivo.
The NAMPT:PARP1 transcript ratio was identified as a predictor of NAMPTi sensitivity across DLBCL subtypes.
Higher antitumor activity was observed in BCL2-translocated GCB-DLBCL when treated with NAMPTi, with synergistic effects seen upon BCL2 inhibition.

Conclusions:

NAMPT inhibition represents a promising therapeutic strategy for BCL2-translocated GCB-DLBCL.
BCL2 translocations can serve as biomarkers for identifying patients who may benefit from NAMPT inhibition.